CSBio CSBio

X
[{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares to Apply its Structure-based Drug Design Expertise in New COVID-19 R&D Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Sosei Group Corporation"},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shionogi to Develop Prophylactic Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Shionogi"},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.8 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Lead Optimization trial for Soil-transmitted\n helminths Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Kao Corporation"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.07 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments in a Hit Identification trial for Chagas disease,\n Leishmaniasis Drug","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Daiichi Sankyo"},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","amount":"$5.4 million","upfrontCash":"Undisclosed","newsHeadline":"Series A Financing of 570 Million Yen Procured by Epsilon Molecular Engineering","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Epsilon Molecular Engineering"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Takeda Pharmaceutical"},{"orgOrder":0,"company":"Shionogi","sponsor":"Nagasaki University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Notice of Collaboration Agreement for the Discovery and Development of Novel Malaria Drugs with Nagasaki University and MMV, Supported by the GHIT Fund","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Shionogi"},{"orgOrder":0,"company":"Shionogi","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$0.9 million","upfrontCash":"Undisclosed","newsHeadline":"GHIT Fund Announces New Investments: A Total of Approximately 260 Million Yen in Shionogi, Takeda Pharmaceutical for New Malaria Drug Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Shionogi"},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"bitBiome and Kaken Pharmaceuticals Sign Joint Research Agreement on The Discovery of Drugs for Infectious Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"bitBiome"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Kaken Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement March 29, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will be used for the research and development of novel antimalarial drugs by Takeda and MMV. The investment will help identify multiple promising compounds in the early stages of research and development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.9 million Upfront Cash: Undisclosed

            Deal Type: Funding March 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the collaboration, Shionogi, Nagasaki University and MMV will accelerate the evaluation and the development of new drugs for the treatment of malaria.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Nagasaki University

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will be used to accelerate the evaluation and the development of new drugs for the treatment of malaria by Shionogi, Nagasaki University and MMV.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.9 million Upfront Cash: Undisclosed

            Deal Type: Funding March 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will be used to advance the pre-clinical development of the SH-879, Company’s novel oral anti-viral small molecules targeting the main protease of SARS-CoV-2 (Mpro), an enzyme critical to SARS-CoV-2 replication, as potential treatments for COVID-19.

            Lead Product(s): SH-879

            Therapeutic Area: Infections and Infectious Diseases Product Name: SH-879

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Wellcome

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding December 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            With these investments, Epsilon Molecular Engineering plans to further promote its next-generation biotechnology-based drug discovery research and development focusing on heavy chain single domain antibodies, VHH antibody.

            Lead Product(s): VHH antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Mitsubishi UFJ Capital

            Deal Size: $5.4 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing December 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funds will be used for Cry5B optimization for Trichuris - whipworm which is beign conducted by Kao Corporation, PATH, University of Massachusetts Medical School.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.8 million Upfront Cash: Undisclosed

            Deal Type: Funding September 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funds will be used for screening project between Daiichi Sankyo RD Novare and DNDi for hit identification of a Chagas disease, Leishmaniasis Drug.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GHIT Fund

            Deal Size: $0.07 million Upfront Cash: Undisclosed

            Deal Type: Funding September 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In a project supported by the Japan Agency for Medical Research and Development (AMED), Shionogi and its subsidiary, UMN Pharma, are pursuing the discovery and development of a recombinant protein vaccine for COVID-19, using their unique technology.

            Lead Product(s): Prophylactic recombinant protein vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Company has initiated a new R&D program to identify novel compounds that block the activity of the SARS-CoV-2 MPro protease (Nsp5), which has been designated as potential target for drug development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY